TORONTO, Feb. 6 /CNW/ - Insception Biosciences Inc., a privately-held
company that develops stem cell treatments, announced today it has received
approval from the Food and Drug Administration (FDA) to begin human clinical
studies of a new stem cell treatment, which offers an alternative to bone
Cord blood, which offers a rich source of blood stem cells, is now
clinically accepted as a viable alternative to bone marrow or peripheral blood
as sources of stem cells for transplantation and treatment of a variety of
blood, cancer and genetic disorders. To date, one of the barriers to the
widespread use of cord blood has been the low number of stem cells in cord
blood samples. This has, by and large, limited its use to pediatric patients.
However, Insception Biosciences' new cellular product, called INSC01, contains
an enriched number of stem cells from umbilical cord blood which will broaden
the use of cord blood stem cells for adult transplants.
"This is a major milestone, not only for Insception but also for the
advancement of cord blood stem cell treatments," says Dr. Laura Grey, VP
Research and Business Development at Insception Biosciences. "Cord blood is
not only an alternative stem cell source to bone marrow, it provides the
significant advantages of being easily collected and can be stored as a frozen
product, which means it is readily available with minimal waiting times.
Ultimately, this technology could be applied in the future to help patients
who cannot find a suitable donor or who cannot afford to wait for a bone
On any given day, there are approximately 6,000 patients in the U.S.
alone requiring a bone marrow transplant but have no donor, according to the
U.S. National Marrow Donor Program. There are also hundreds of Canadians in
need of bone marrow transplants each year to treat a wide variety of
illnesses, including blood-related diseases such as leukemia, and inherited
immune system and metabolic disorders, according to the Canadian Blood
Services. For most of these patients, a bone marrow transplant may be the last
and best chance for recovery from a serious illness. Many will die waiting for
a suitable match.
"Without question, umbilical cord blood has already had a dramatic impact
on the application of bone marrow transplantation, particularly for those
awaiting a bone marrow transplant who cannot find a matched donor. However, it
is also unequivocally clear that the number of stem cells in an umbilical cord
blood sample is the most critical determinant influencing the probability of a
cure," says Dr. John Wagner, director of the Blood and Marrow Transplant
Program at the University of Minnesota, one of the world's most experienced
cord blood transplant centers. "For this reason, products like Insception
Biosciences' INSCO1, based on expanding the number of stem cells in cord
blood, are critical to dramatically advancing the application of cord blood
Increasingly, cord blood is being used for bone marrow transplants
worldwide. Cord blood offers clear advantages including easy collection, lower
risk of viral transmission, reduced risk of graft versus host disease, and is
storable as a frozen product, which means it is readily available without any
long waiting times.
A growing number of new parents are opting to store their children's cord
blood for potential future use. Insception houses the largest inventory of
cord blood samples in Canada and is setting industry standards for quality in
umbilical cord blood banking and stem cell research. Currently, public cord
blood banking options are limited in Canada although considerable efforts are
afoot to establish a national public cord blood bank. INSC01 provides an
opportunity to extend the use of cord blood samples stored in both the private
and public cord blood banks.
"Insception Biosciences is committed to remaining at the leading edge of
stem cell research and cord blood banking to further advance stem cell
treatments," says Joan Yates, President and COO at Insception Biosciences.
"Every family should be made aware of the potential value of umbilical cord
blood before the birth of their child so they can make an informed decision
about their cord blood banking options."
Insception Biosciences Inc. has established itself as a leader in the
field of umbilical cord blood cellular therapies. The company operates the
largest cord blood program in Canada at its state-of-the-art facility located
in Toronto, Ontario, Canada. Insception's research and development division is
developing a pipeline of cellular therapy products to improve on and extend
the medical uses of cord blood. These include products for blood (bone marrow)
applications and for non-blood applications such as peripheral vascular
disease, neurological disorders and diabetes. For more information on
Insception, visit www.insception.com.
For further information:
For further information: Media Contacts: Angela Gurley, Ketchum on
behalf of Insception Biosciences Inc., (416) 355-7415,
email@example.com; Lindsey Coulter, Ketchum on behalf of Insception
Biosciences Inc., (416) 355-7430, firstname.lastname@example.org